Displaying posts categorized under

Clinical Trials

Clinical Potential of Biological Response Modifiers Combined with Chemotherapy for Gastric Cancer

The most effective treatment for gastric cancer is complete surgical resection with lymphadenectomy. However, a number of patients experience recurrence of the cancer even after curative surgery. This review focuses on comparative trials studying the use of adjuvant therapy with chemotherapy plus immunotherapy in the treatment of patients with curatively resected gastric cancer. […]

Clinical Experience in the Use of PSP

There is no really effective treatment for moderate and advanced stages of esophageal carcinoma. Although surgery for the earlier cases has been able to give a 5 years survival rate of 28.7%, such operable cases are relatively few. By far the greater majority are already in stage III to IV when first seen in the clinic, and radiotherapy alone in these cases has given a 5 years survival rate of only 8-14%. In order to improve treatment results, a variety of chemotherapeutic agents have been used in combination surgery, but so far no really effective drug has been found […]

Antitumor effects of residual tumor after cryoablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model

Cryoablation is a low-invasive surgical treatment for malignant tumors. It may induce an immunological response leading to the eradication of distant metastases or alternatively it might promote the growth of residual tumors. In this paper we confirm the occurrence of both phenomena and we describe the preventive effect of a protein-bound polysaccharide preparation. Metastatic liver tumors were produced […]

Alternating immunotherapy of advanced gastric carcinoma: A randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection

A total of 103 patients with advanced gastric carcinoma were randomized after curative surgery to receive an alternate administration of carabzilquinone (CQ) and PSK (Krestin) or carbazilquinone alone. Each course of therapies started 1 week after the surgical operation and therapy schedules consisted of 9 courses. In each course of 6 weeks, CQ was administered on day 0, 8, and 15. In combined immunochemotherapy group, PSK was given orally in 3-divided doses of 2g/m^2/day from the day of the third CQ administration for consecutive 4 weeks. Estimated survival rate and cumulative survival curve [….]

Evaluation of widely consumed botanicals as immunological adjuvants.

Some, but not all, botanicals purported to be immune stimulants had adjuvant activity in our model. PSK and Astragalus were surprisingly active and are being further fractionated to identify the most active adjuvant components.

Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection.

A total of 103 patients with advanced gastric carcinoma were randomized after curative surgery to receive an alternate administration of carbazilquinone (CQ) and PSK (Krestin) or carbazilquinone alone. Each course of herapies started 1 week after the surgical operation and therapy schedules consisted of 9 courses. In each course of 6 weeks […]

Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.

PURPOSE: Intravenous fluorouracil and leucovorin for six to eight months is currently a standard adjuvant treatment for Stage III colon cancer; however, this regimen is complex, inconvenient, and has a high intolerability. Adjuvant chemotherapies are claimed for objective response rates with an acceptable safety profile and complexity. We investigated […]

Mushroom immunutrition in Chronic Fatigue Immune Dysfunction Syndrome

In the recently published edition of the Journal of Integrated Medicine (Online version), Dr. Jean Monro of the Breakspear Hospital outlines the impact of Coriolus versicolor supplementation as immunonutrition in thirty-six (36) Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) patients over a six week period.

1) Natural Killer Cells–before treatment the average NK cell level was average=129.64/mm3. After treatment this had increased to 175/mm3, an increase of 35%.

2) T cells (CD3 CD26)–there was increased activation in 66% of patients and T cell depression in 22% of patients. T cell level was unchanged in 11% of the patients. […]

Clinical Trial Results Show Proof-of-Concept For Use Of Coriolus Versicolor As Immunonutrition In HPV Patients With Cervical Lesions (LSIL)

(Medical News Today – 4/29/2008) Result: Of the 39 patients who completed one year of follow-up, 18 took Coriolus supplementation, while the other 21 patients received no therapy (Control group). After 1 year 13 of the 18 patients in the Coriolus group showed normal cervical cytology (72.5%) while only 10 of the patients in the control group did (47.5%).

Of the 39 patients, 22 were positive for high risk HPV subtypes.10 of these patients were in the Coriolus group and 12 in the control group. After 1 year 9 of the 10 in the Coriolus group had reverted to HPV- status (90%) while only 1 of the 12 in the control group had (8.5%). […]

Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx.

A controlled study using adjuvant PSK immunotherapy in patients with nasopharyngeal carcinoma was initiated with the aim of improving survival by enhancing the host immune system against tumour cells. A total of 38 patients were randomly selected, all of whom had previously received radiotherapy with or without chemotherapy. Eight patients in the PSK immunotherapy group (n = 21) developed […]